Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

Table 4 Urinary symptoms improvement after switching from tolterodine ER to fesoterodine according to fesoterodine dose at the study visit

Urinary symptom (not at all = 0 to quite a lot = 5)	Total	4 mg	8 mg	p value between groups
Worry
Frequency	3.2 (3.1-3.3)	3.4 (3.3-3.5)	3.1 (3.0-3.2)	0.001
Incontinence during sexual attempt	2.2 (2.2-2.3)	2.1 (1.9-2.2)	2.2 (2.1-2.4)	0.075
Nocturia	3.0 (2.9-3.1)	3.2 (3.1-3.4)	3.0 (2.9-3.1)	0.010
Frequency of infections	2.4 (2.3-2.5)	2.4 (2.2-2.5)	2.4 (2.3-2.5)	0.812
Urgency	3.2 (3.1-3.3)	3.4 (3.2-3.5)	3.2 (3.1-3.3)	0.026
Bladder pain	2.3 (2.3-2.4)	2.4 (2.3-2.6)	2.3 (2.2-2.4)	0.207
Urge incontinence	3.1 (3.0-3.3)	3.3 (3.2-3.5)	3.1 (3.0-3.2)	0.008
Urinary difficulties	2.2 (2.1-2.3)	2.2 (2.0-2.3)	2.2 (2.1-2.3)	0.691
Stress incontinence	2.2 (2.1-2.3)	2.1 (1.9-2.3)	2.2 (2.1-2.3)	0.304
Bother
Urinary frequency	3.2 (3.2-3.3)	3.4 (3.3-3.6)	3.2 (3.1-3.2)	0.001
Strong desire to urinate	3.3 (3.2-3.4)	3.5 (3.4-3.7)	3.2 (3.1-3.3)	<0.001
Urine loss associated with a strong desire to urinate	3.1 (3.0-3.2)	3.3 (3.1-3.5)	3.0 (2.9-3.1)	0.007
Interference with daily-living activities
Usual activities	3.0 (2.9-3.1)	3.1 (3.0-3.3)	3.0 (2.9-3.1)	0.119
Leisure	3.1 (3.0-3.2)	3.2 (3.1-3.4)	3.0 (2.9-3.1)	0.032
Work/domestic activities	2.5 (2.4-2.6)	2.5 (2.3-2.6)	2.4 (2.3-2.5)	0.717

p significance level adjusted by sex, driven of treatment change, treatment adherence, treatment length, reason for switching; Values are mean (95% Confidence Interval).

ISSN: 1471-2490